ArticleCell death & disease2026
OSCAR functions as a collagen I receptor to suppress hippo signaling and reprogram lipid metabolism in clear-cell renal cell carcinoma.
Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Extensive extracellular matrix (ECM) remodeling is a hallmark of clear-cell renal cell carcinoma (ccRCC), and collagen I has been widely implicated in ccRCC progression through multiple oncogenic pathways. However, the receptor-level mechanisms by which collagen I engages specific signaling and metabolic programs remain incompletely understood. Here, we demonstrate that collagen I is highly expressed in ccRCC and predicts poor prognosis. We further uncover OSCAR as its key functional receptor, mediating tumor progression and metabolic reprogramming through Hippo signaling modulation. Mechanistically, collagen I binding induces OSCAR internalization and its interaction with the Hippo regulator SAV1. This disrupts SAV1 membrane localization, allowing YAP to enter the nucleus and activate downstream genes, which enhances proliferation, metastasis, and de novo fatty acid synthesis. Furthermore, we designed a lipid nanoparticle (CCP-LNP) that blocks the collagen I-OSCAR interaction and effectively suppresses tumor progression in vitro and in vivo. These findings reveal a collagen I-OSCAR-Hippo axis that links ECM signaling to metabolic reprogramming and suggest a potential therapeutic strategy for ccRCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.